Sonnet BioTherapeutics Holdings (SONN)

Sonnet BioTherapeutics Holdings (SONN) Income Statement


Sonnet BioTherapeutics Holdings Income Statement

Last quarter (Q3 2023), Sonnet BioTherapeutics Holdings's total revenue was $36.85K, a decrease of -40.63% from the same quarter last year. In Q3, Sonnet BioTherapeutics Holdings's net income was $-3.95M. See Sonnet BioTherapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Sep 22Sep 21Sep 20Sep 19
Total Revenue
$ 173.30K$ 349.94K$ 483.63K$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ 110.55K$ 349.94K---
Operating Expense
$ 41.02K$ -30.02M$ 25.57M$ 17.41M$ 4.71M
Operating Income
$ -11.17M$ -29.67M$ -25.09M$ -17.41M$ -4.71M
Net Non Operating Interest Income Expense
--$ 15.00$ 20.68K$ -162.87K
Other Income Expense
$ -131.67K$ -300.00K$ 103.46K$ -6.87M-
Pretax Income
$ -11.19M$ -29.72M$ -24.98M$ -24.27M$ -4.87M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -11.19M$ -29.72M$ -24.98M$ -65.60M$ -4.87M
Basic EPS
$ -2.93$ -6.84$ -14.28$ -6.96$ -23.66
Diluted EPS
$ -2.13-$ -14.28$ -6.96$ -23.66
Basic Average Shares
$ 57.26M$ 4.35M$ 1.75M$ 9.42M$ 205.70K
Diluted Average Shares
$ 51.43M-$ 1.75M$ 9.42M$ 205.70K
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 41.02K$ -30.02M$ 25.57M$ 17.41M$ 4.71M
Net Income From Continuing And Discontinued Operation
$ -22.59M$ -29.72M$ -24.98M$ -24.27M$ -4.87M
Normalized Income
$ -10.49M-$ -24.96M$ -17.39M$ -4.87M
Interest Expense
$ -11.13M$ -29.72M$ -25.09M$ -17.41M$ -4.71M
$ -11.06M$ -29.63M$ -24.99M$ -17.35M$ -4.71M
Currency in USD

Sonnet BioTherapeutics Holdings Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis